This study provides new perspectives on NK cell phenotype in solid tumors after TLR7/8 agonist administration, and our findings on NK cell dynamics during treatment with Toll-like receptor 7/8 agonists in melanoma could be used to establish new approaches in cancer immunotherapy. The gene discussed is TLR7; the disease is melanoma.